Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) EBITDA Margin (2016 - 2025)

Altimmune (ALT) has disclosed EBITDA Margin for 16 consecutive years, with 379820.0% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 7014000.0% to 379820.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 420430.0%, a 22188962.0% decrease, with the full-year FY2024 number at 475140.0%, down 45443014.0% from a year prior.
  • EBITDA Margin was 379820.0% for Q3 2025 at Altimmune, up from 443640.0% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 729.13% in Q4 2021 to a low of 1182950.0% in Q3 2022.
  • A 5-year average of 273277.4% and a median of 252837.5% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -116173949bps in 2022, then surged 117725525bps in 2023.
  • Altimmune's EBITDA Margin stood at 729.13% in 2021, then tumbled by -11286bps to 83015.38% in 2022, then decreased by -3bps to 85191.89% in 2023, then tumbled by -447bps to 466160.0% in 2024, then increased by 19bps to 379820.0% in 2025.
  • Per Business Quant, the three most recent readings for ALT's EBITDA Margin are 379820.0% (Q3 2025), 443640.0% (Q2 2025), and 392100.0% (Q1 2025).